In the early days, producing enough exosomes for a single patient was a labor-intensive "Craft," but in 2026, the Exosome Therapeutics Market has entered its "Industrial Age." The shift from "Manual Ultracentrifugation" to "Automated Tangential Flow Filtration" and "Chromatography" has increased production yields by over 300%. This "Manufacturing Revolution" is critical because it lowers the...